Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corn oil QHC approved

This article was originally published in The Tan Sheet

Executive Summary

Scientific evidence supports a substance/disease relationship linking corn oil consumption to a reduced risk of coronary heart disease, but FDA "believes that the scientific evidence represents a very low level of comfort among qualified scientists that the claimed relationship is scientifically valid," the agency says in a qualified health claim approval March 26. Therefore, enforcement discretion will be exercised for label statements that provide a non-misleading description of the strength of the scientific evidence, such as "very limited and preliminary scientific evidence suggests," FDA notes. The Wood Burditt Group submitted a petition in April 2006 seeking approval of claims such as "substituting corn oil for solid fats may reduce your risk of heart disease." The agency points out in its approval letter that among the intervention studies submitted to support the claim, three did not measure a validated surrogate endpoint of CHD, 17 did not include a control group consuming saturated fatty acids, six did not perform statistical analysis between the intervention and control groups and 17 had a duration of intervention that was too short (less than three weeks)...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel